caa a22 4500 606204334 CHVBK 20210128101001.0 cr unu---uuuuu 210128e20150701xx s 000 0 eng 10.1007/s10388-014-0468-y doi (NATIONALLICENCE)springer-10.1007/s10388-014-0468-y Association between pharmacokinetic variables and neutropenia after treatment with docetaxel, cisplatin, and 5-fluorouracil in patients with esophageal squamous cell carcinoma [Elektronische Daten] [Mitsuhiro Sugawara, Chikatoshi Katada, Toshiaki Komatsu, Kaoru Takahashi, Mizutomo Azuma, Katsuhiko Higuchi, Wasaburo Koizumi, Koichiro Atsuda] Background: Combined chemotherapy with cisplatin, 5-fluorouracil, and docetaxel (DCF) is a promising regimen for the treatment of esophageal squamous cell carcinoma (ESCC). However, careful attention must be paid to severe neutropenia. Methods: A total of 17 patients with ESCC who received DCF therapy (docetaxel 75mg/m2 on day 1, cisplatin 75mg/m2 on day 1, and 5-fluorouracil 750mg/m2 on days 1-5) were studied from December 2010 through May 2012. We assessed the relation between neutropenia and the plasma concentration of each anticancer drug during the first course of DCF therapy. Results: The maximum plasma concentration (C max) (mean±SD) of docetaxel was 1,929±458ng/mL, while that of cisplatin was 2,870±410ng/mL, and that of 5-fluorouracil was 448±121ng/mL. The area under the plasma concentration-time curve (AUC) (mean±SD) as calculated by MOMENT analysis was 2,428±513ng/mLh for docetaxel and 135,950±22,330ng/mLh for cisplatin. The AUC of 5-fluorouracil was not calculated. Higher C max and AUC values for docetaxel were associated with trends toward lower nadir absolute neutrophil counts (ANCs). The C max of docetaxel reflected the AUC of docetaxel. Neither the C max nor AUC of docetaxel was related to the occurrence of febrile neutropenia. Conclusions: Higher C max or AUC values of docetaxel are associated with a trend toward lower nadir ANCs in patients with ESCC who receive DCF therapy. The C max of docetaxel, which is assessable immediately after starting treatment, might be useful for predicting the severity of the nadir ANC or for selecting the management method. The Japan Esophageal Society and Springer Japan, 2014 Esophageal cancer nationallicence DCF nationallicence Neutropenia nationallicence Pharmacokinetics nationallicence Docetaxel nationallicence Sugawara Mitsuhiro Department of Pharmacy, Kitasato University Hospital, 1-15-1 Kitasato, Minami-ku, 252-0375, Sagamihara, Japan aut Katada Chikatoshi Department of Gastroenterology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, 252-0374, Sagamihara, Japan aut Komatsu Toshiaki Department of Pharmacy, Kitasato University Hospital, 1-15-1 Kitasato, Minami-ku, 252-0375, Sagamihara, Japan aut Takahashi Kaoru Department of Nursing, Kitasato University Hospital, 1-15-1 Kitasato, Minami-ku, 252-0375, Sagamihara, Japan aut Azuma Mizutomo Department of Gastroenterology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, 252-0374, Sagamihara, Japan aut Higuchi Katsuhiko Department of Gastroenterology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, 252-0374, Sagamihara, Japan aut Koizumi Wasaburo Department of Gastroenterology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, 252-0374, Sagamihara, Japan aut Atsuda Koichiro Division of Clinical Pharmacy, Research and Education Center of Clinical Pharmacy, Kitasato University School of Pharmacy, 1-15-1 Kitasato, Minami-ku, 252-0375, Sagamihara, Japan aut Esophagus Springer Japan 12/3(2015-07-01), 209-218 1612-9059 12:3<209 2015 12 10388 https://doi.org/10.1007/s10388-014-0468-y text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10388-014-0468-y text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Sugawara Mitsuhiro Department of Pharmacy, Kitasato University Hospital, 1-15-1 Kitasato, Minami-ku, 252-0375, Sagamihara, Japan aut NATIONALLICENCE 700 1- Katada Chikatoshi Department of Gastroenterology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, 252-0374, Sagamihara, Japan aut NATIONALLICENCE 700 1- Komatsu Toshiaki Department of Pharmacy, Kitasato University Hospital, 1-15-1 Kitasato, Minami-ku, 252-0375, Sagamihara, Japan aut NATIONALLICENCE 700 1- Takahashi Kaoru Department of Nursing, Kitasato University Hospital, 1-15-1 Kitasato, Minami-ku, 252-0375, Sagamihara, Japan aut NATIONALLICENCE 700 1- Azuma Mizutomo Department of Gastroenterology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, 252-0374, Sagamihara, Japan aut NATIONALLICENCE 700 1- Higuchi Katsuhiko Department of Gastroenterology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, 252-0374, Sagamihara, Japan aut NATIONALLICENCE 700 1- Koizumi Wasaburo Department of Gastroenterology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, 252-0374, Sagamihara, Japan aut NATIONALLICENCE 700 1- Atsuda Koichiro Division of Clinical Pharmacy, Research and Education Center of Clinical Pharmacy, Kitasato University School of Pharmacy, 1-15-1 Kitasato, Minami-ku, 252-0375, Sagamihara, Japan aut NATIONALLICENCE 773 0- Esophagus Springer Japan 12/3(2015-07-01), 209-218 1612-9059 12:3<209 2015 12 10388